questionsmedicales.fr
Tumeurs
Tumeurs par type histologique
Leucémies
Leucémies : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Leucémie
Biopsie
Analyse sanguine
Hémogramme
Cytométrie en flux
Tests génétiques
Globules blancs
Anémie
Plaquettes
Radiographie
IRM
Extension de la maladie
Biopsie médullaire
Cellules leucémiques
Moelle osseuse
Symptômes
5
Fatigue
Fièvre
Infections
Perte de poids
Symptômes
Leucémie
Système immunitaire
Infections
Leucémie
Douleurs osseuses
Cellules leucémiques
Leucémie
Sueurs nocturnes
Symptômes
Leucémie
Prévention
5
Prévention
Facteurs de risque
Leucémie
Facteurs de risque
Radiations
Maladies génétiques
Tabagisme
Risque
Leucémie
Infections virales
Virus d'Epstein-Barr
Leucémie
Alimentation
Prévention
Santé générale
Traitements
5
Chimiothérapie
Radiothérapie
Greffe de moelle osseuse
Chimiothérapie
Types de leucémie
Efficacité
Greffe de moelle osseuse
Cellules souches
Traitement
Effets secondaires
Chimiothérapie
Nausées
Radiothérapie
Traitement
Complications
Complications
5
Complications
Infections
Saignements
Coagulation sanguine
Saignements
Leucémie
Problèmes cardiaques
Traitements
Leucémie
Infections
Système immunitaire
Leucémie
Douleurs chroniques
Traitements
Leucémie
Facteurs de risque
5
Facteurs de risque
Radiations
Antécédents familiaux
Troubles génétiques
Syndrome de Down
Risque
Antécédents
Chimiothérapie
Risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Leucémies : Questions médicales les plus fréquentes",
"headline": "Leucémies : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Leucémies : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Leucémies"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs par type histologique",
"url": "https://questionsmedicales.fr/mesh/D009370",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs par type histologique",
"code": {
"@type": "MedicalCode",
"code": "D009370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie myéloïde",
"alternateName": "Leukemia, Myeloid",
"url": "https://questionsmedicales.fr/mesh/D007951",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D007951",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myéloïde",
"alternateName": "Leukemia, Myeloid, Acute",
"url": "https://questionsmedicales.fr/mesh/D015470",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D015470",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myélomonocytaire",
"alternateName": "Leukemia, Myelomonocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015479",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myélomonocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.520"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Leucémies",
"alternateName": "Leukemia",
"code": {
"@type": "MedicalCode",
"code": "D007938",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kumaran Mudaliar",
"url": "https://questionsmedicales.fr/author/Kumaran%20Mudaliar",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Laboratory Medicine Loyola University Medical Center Maywood Illinois USA."
}
},
{
"@type": "Person",
"name": "Gregor Eisenwort",
"url": "https://questionsmedicales.fr/author/Gregor%20Eisenwort",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Irina Sadovnik",
"url": "https://questionsmedicales.fr/author/Irina%20Sadovnik",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Alexandra Keller",
"url": "https://questionsmedicales.fr/author/Alexandra%20Keller",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Daniela Berger",
"url": "https://questionsmedicales.fr/author/Daniela%20Berger",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Fluoroscopic Intraoperative Breast Neoplasm and Node Detection.",
"datePublished": "2023-01-10",
"url": "https://questionsmedicales.fr/article/36728380",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/XCS.0000000000000548"
}
},
{
"@type": "ScholarlyArticle",
"name": "Metastatic primary breast neuroendocrine neoplasms: a case series.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36314732",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/imj.15961"
}
},
{
"@type": "ScholarlyArticle",
"name": "Galectin-3 as a biomarker in breast neoplasms: Mechanisms and applications in patient care.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36125083",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/JLB.5MR0822-673R"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36008514",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-18712-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37473463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2023.112952"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Leucémies",
"item": "https://questionsmedicales.fr/mesh/D007938"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Leucémies - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Leucémies",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Leucémies",
"description": "Comment diagnostique-t-on une leucémie ?\nQuels tests sont utilisés pour confirmer une leucémie ?\nQuels signes indiquent une leucémie lors des tests ?\nLes examens d'imagerie sont-ils nécessaires ?\nQuelle est l'importance de la biopsie médullaire ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Breast+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Leucémies",
"description": "Quels sont les symptômes courants de la leucémie ?\nLa perte de poids est-elle un symptôme de leucémie ?\nComment la leucémie affecte-t-elle le système immunitaire ?\nLes douleurs osseuses sont-elles liées à la leucémie ?\nLes sueurs nocturnes sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Breast+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Leucémies",
"description": "Peut-on prévenir la leucémie ?\nQuels facteurs de risque sont associés à la leucémie ?\nLe tabagisme augmente-t-il le risque de leucémie ?\nLes infections virales peuvent-elles causer la leucémie ?\nL'alimentation joue-t-elle un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Breast+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Leucémies",
"description": "Quels sont les traitements principaux de la leucémie ?\nLa chimiothérapie est-elle efficace contre toutes les leucémies ?\nQu'est-ce qu'une greffe de moelle osseuse ?\nQuels sont les effets secondaires de la chimiothérapie ?\nLa radiothérapie est-elle utilisée pour traiter la leucémie ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Breast+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Leucémies",
"description": "Quelles sont les complications possibles de la leucémie ?\nComment la leucémie affecte-t-elle la coagulation sanguine ?\nLes leucémies peuvent-elles entraîner des problèmes cardiaques ?\nQuelles infections sont fréquentes chez les patients leucémiques ?\nLes leucémies peuvent-elles causer des douleurs chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Breast+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Leucémies",
"description": "Quels sont les principaux facteurs de risque de leucémie ?\nL'âge influence-t-il le risque de leucémie ?\nLes troubles génétiques augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de leucémie ?\nLes antécédents de chimiothérapie augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Breast+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une leucémie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, une biopsie de moelle osseuse et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une leucémie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'hémogramme, la cytométrie en flux et les tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une leucémie lors des tests ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des globules blancs, une anémie et des plaquettes basses peuvent indiquer une leucémie."
}
},
{
"@type": "Question",
"name": "Les examens d'imagerie sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens comme la radiographie ou l'IRM peuvent aider à évaluer l'extension de la maladie."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la biopsie médullaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie médullaire permet d'évaluer la présence de cellules leucémiques dans la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la leucémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, infections fréquentes et saignements faciles."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle un symptôme de leucémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut être un symptôme de leucémie."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie affaiblit le système immunitaire, rendant le corps plus vulnérable aux infections."
}
},
{
"@type": "Question",
"name": "Les douleurs osseuses sont-elles liées à la leucémie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs osseuses peuvent survenir en raison de l'accumulation de cellules leucémiques."
}
},
{
"@type": "Question",
"name": "Les sueurs nocturnes sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les sueurs nocturnes peuvent être un symptôme courant chez les patients leucémiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la leucémie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à la leucémie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition aux radiations, certains produits chimiques et des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque de leucémie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour certains types de leucémie."
}
},
{
"@type": "Question",
"name": "Les infections virales peuvent-elles causer la leucémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, sont liées à un risque accru de leucémie."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut contribuer à la santé générale, mais ne prévient pas spécifiquement la leucémie."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements principaux de la leucémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et la greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace contre toutes les leucémies ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est efficace pour de nombreux types de leucémie, mais pas tous."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une greffe de moelle osseuse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui remplace la moelle osseuse malade par des cellules souches saines."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la chimiothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée pour traiter la leucémie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter certaines leucémies, surtout en cas de complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la leucémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections graves, saignements, et complications liées aux traitements."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle la coagulation sanguine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie peut entraîner des troubles de la coagulation, augmentant le risque de saignements."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles entraîner des problèmes cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements de la leucémie peuvent augmenter le risque de problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quelles infections sont fréquentes chez les patients leucémiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections bactériennes et fongiques sont courantes en raison d'un système immunitaire affaibli."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles causer des douleurs chroniques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs chroniques peuvent survenir en raison de la maladie ou des traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de leucémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'exposition aux radiations, certains produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de leucémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de leucémie augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les troubles génétiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme le syndrome de Down augmentent le risque de leucémie."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque de leucémie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes ont généralement un risque plus élevé de leucémie que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents de chimiothérapie augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir reçu une chimiothérapie pour un autre cancer peut augmenter le risque de leucémie."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
└─
Leucémie myéloïde
Leukemia, Myeloid
D007951 -
C04.557.337.539
└─└─
Leucémie aigüe myéloïde
Leukemia, Myeloid, Acute
D015470 -
C04.557.337.539.275
└─└─
Leucémie aigüe myélomonocytaire
Leukemia, Myelomonocytic, Acute
D015479 -
C04.557.337.539.520
└─└─└─
Leucémie aiguë à basophiles
Leukemia, Basophilic, Acute
D015471 -
C04.557.337.539.275.125
└─└─└─
Leucémie aigüe à éosinophiles
Leukemia, Eosinophilic, Acute
D015472 -
C04.557.337.539.275.300
└─└─└─
Leucémie aigüe mégacaryoblastique
Leukemia, Megakaryoblastic, Acute
D007947 -
C04.557.337.539.275.450
└─└─└─
Leucémie aigüe monoblastique
Leukemia, Monocytic, Acute
D007948 -
C04.557.337.539.275.484
└─└─└─
Leucémie aiguë promyélocytaire
Leukemia, Promyelocytic, Acute
D015473 -
C04.557.337.539.275.700
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
Preoperative localization is necessary for nonpalpable breast lesions. A novel procedure, fluoroscopic intraoperative neoplasm and node detection (FIND), obviates the preoperative painful and potentia...
This is an IRB-approved retrospective study (September 2016 to March 2021). Electronic chart review identified breast and axillary node procedures using wire localization (WL) or FIND. Primary outcome...
We identified 459 patients, of whom 116 (25.3%) underwent FIND and 343 (74.7%) WL. Of these, 68.1% of FIND and 72.0% of WL procedures were for malignant lesions. Final margin positivity was 5.1% (4 of...
FIND has lower positive margin rates and a trend towards lower re-excision rates compared with WL, proving its value in localizing nonpalpable breast lesions. It also offers accurate localization of a...
Breast neuroendocrine neoplasms represent a rare subtype of breast cancer which have not been well studied or characterised, particularly in the metastatic setting....
To present clinicopathological characteristics, treatment and outcomes of a series of patients with metastatic neuroendocrine carcinoma of the breast and review the current literature....
We performed a retrospective review to identify and describe patients with metastatic neuroendocrine carcinoma of the breast at our centre between 2011 and 2021. Medical records, pathology and imaging...
We present a series of seven female patients with metastatic neuroendocrine carcinoma of the breast, as defined by the World Health Organization classification, over a period of 10 years (2011-2021) f...
This series shows the use of multiple modalities in treating this disease, with different sequencing in different patients. Despite multiple modalities used in the first-line setting, first-line PFS r...
Galectin-3 is a member of the lectin family encoded by the LGALS3 gene on chromosome 14. It is secreted by a wide range of immune cells and mammary tumor cells. Through its activity on the tumor micro...
Breast cancer causes morbidity and mortality among women worldwide, despite much research illuminating the genetic basis of this disease. Anti-angiogenesis therapies have been widely studied, although...
Long-term complications are becoming more important as the survival rate of breast cancer improves. Treatment-related myeloid neoplasm is an important long-term complication in breast cancer survivors...
We evaluated the incidence and risk factors for the development of treatment-related acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) in patients treated with early breast cancer....
We accessed the national Korean database to identify 153,565 patients diagnosed with breast cancer between January 2007 and October 2016 who underwent surgery for breast cancer. We estimated the cumul...
Of 153,575 patients, 79,321 received anthracycline-based adjuvant therapy, 14,317 received adjuvant therapy without anthracyclines and 46,657 did not receive adjuvant chemotherapy. Overall, 120 develo...
This study found that anthracycline-based adjuvant therapy significantly increased the risk of AML/MDS in Korean breast cancer patients, with the risk persisting for at least 10 years. While the cumul...
Neuroendocrine neoplasms (NENs) of the breast are rare and not well-studied. NEN are subcategorized as well-differentiated neuroendocrine tumor (NET) and poorly differentiated neuroendocrine carcinoma...
Between 2004 and 2015, 420 NET, 205 NEC, 146 Adenocarcinoma with NE differentiation (ACNED) and 1,479,520 of invasive carcinoma, not otherwise specified (IC-NOS) of the breast were identified in the N...
After adjusting for other prognostic factors, both NET and NEC of the breast showed significantly worse OS than IC-NOS (HR (95% CI) = 1.41 (1.17, 1.72), p = 0.005 and HR (95% CI) = 2.11 (1.67, 2.67), ...
NEN is a unique pathologic and clinical entity, which has worse clinical outcome compared to IC-NOS of the breast. Current therapeutics used in the treatment of IC-NOS improve, but do not fully mitiga...
Breast cancer is the most lethal malignancy for women worldwide. Developed countries, such as Portugal, Spain, and the United States, have declining mortality rates due to breast cancer; however, in d...
Data were obtained from the National Health System Department of Informatics (DATASUS), maintained by the Brazilian Ministry of Health, which includes the registers of hospitalization and mortality by...
From 2008 to 2019, 643,822 hospital admissions due to malignant neoplasm of breast were reported in Brazil, of which the South and Southeast regions were the most prevalent. Higher hospitalization rat...
We have shown an increase in morbidity and mortality over time, which is dependent on patients' age and region. The results presented here may contribute to the ongoing discussion about the role and f...
To explore the differential diagnosis of benign and malignant papillary neoplasms on MRI with non-mass enhancement....
A total of 48 patients with surgically confirmed papillary neoplasms showing non-mass enhancement were included. Clinical findings, mammography and MRI features were retrospectively analyzed, and lesi...
Fifty-three papillary neoplasms were shown on MR images with non-mass enhancement, including 33 intraductal papilloma and 20 papillary carcinomas (9 intraductal papillary carcinoma, 6 solid papillary ...
Papillary carcinoma on MRI with non-mass enhancement mostly showed internal clustered ring enhancement, while papilloma mostly showed internal clumped enhancement; additional mammography is of limited...
Primary neuroendocrine neoplasms of the breast (Br-NENs) are rare. The classification has been updated in recent years making interpretation of the data published challenging. It is unclear whether ne...
The database for breast cancer patients treated between 2009 and 2022 at the Maria Sklodowska-Curie National Research Institute of Oncology Branch Krakow was explored to search for Br-NENs. Patients' ...
We included 22 females with Br-NEN without metastases at the time of diagnosis. The median age was 64 years (range: 28-88), Of the cases, 18 were hormone receptor positive, all were HER-2 negative, th...
Br-NENs represent a heterogenous group of diseases, lacking data from prospective studies or clinical trials. There are no established treatment standards tailored for Br-NENs. Our patients' cohort ex...
We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and ...
